Alpha-1 Antitrypsin Deficiency and Tobacco Smoking: Exploring Risk Factors and Smoking Cessation in a Registry Population

References

• Brantly ML, Wittes JT, Vogelmeier CF, et al. Use of a highly purified Alpha 1-antitrypsin standard to establish ranges for the common normal and deficient Alpha 1-antitrypsin phenotypes. Chest. 1991;100(3):703–708. DOI:10.1378/chest.100.3.703
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with Alpha 1-antitrypsin deficiency (PiZZ). Thorax. 1997;52(3):244–248. DOI:10.1136/thx.52.3.244
   PubMed Web of Science ®Google Scholar
• Carroll TP, O'Connor CA, Floyd O, et al. The prevalence of Alpha-1 antitrypsin deficiency in Ireland. Respir Res. 2011;12:91. DOI:10.1186/1465-9921-12-91
   PubMed Web of Science ®Google Scholar
• Blanco I, de Serres FJ, Carcaba V, et al. Alpha-1 antitrypsin deficiency PI*Z and PI*S gene frequency distribution using on maps of the world by an inverse distance weighting (IDW) multivariate interpolation method. Hepat Mon. 2012;12(10 HCC):e7434. DOI:10.5812/hepatmon.7434
   PubMed Web of Science ®Google Scholar
• Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189(4):419–427. DOI:10.1164/rccm.201311-1984OC
   PubMed Web of Science ®Google Scholar
• Foreman MG, Wilson C, DeMeo DL, et al. Alpha-1 antitrypsin PiMZ genotype is associated with chronic obstructive pulmonary disease in two racial groups. Ann Am Thorac Soc. 2017;14(8):1280–1287. DOI:10.1513/AnnalsATS.201611-838OC
   PubMed Web of Science ®Google Scholar
• Ortega VE, Li X, O’Neal WK, et al. The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS. Am J Respir Crit Care Med. 2020;201(5):540–554. DOI:10.1164/rccm.201904-0769OC
   PubMed Web of Science ®Google Scholar
• Franciosi AN, Hobbs BD, McElvaney OJ, et al. Clarifying the risk of lung disease in SZ Alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2020;202(1):73–82. DOI:10.1164/rccm.202002-0262OC
   PubMed Web of Science ®Google Scholar
• Franciosi AN, Carroll TP, McElvaney NG. SZ alpha-1 antitrypsin deficiency and pulmonary disease: more like MZ, not like ZZ. Thorax. 2020 Sep 11:thoraxjnl-2020-215250. doi: 10.1136/thoraxjnl-2020-215250.
   Google Scholar
• Turino GM, Barker AF, Brantly ML, et al. Clinical features of individuals with PI*SZ phenotype of Alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1718–1725. DOI:10.1164/ajrccm.154.6.8970361
   PubMed Web of Science ®Google Scholar
• Byng D, Lutter JI, Wacker ME, et al. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. COPD. 2019;14:1423–1439. DOI:10.2147/COPD.S201899
   Google Scholar
• Wacker ME, Jorres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46. DOI:10.1016/j.rmed.2015.12.001
   PubMed Web of Science ®Google Scholar
• Hollands GJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016;352:i1102. DOI:10.1136/bmj.i1102
   PubMed Web of Science ®Google Scholar
• Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for Alpha-1 antitrypsin deficiency. Ann Behav Med. 2007;33(1):22–28. DOI:10.1207/s15324796abm3301_3
   PubMed Web of Science ®Google Scholar
• Holm KE, Mannino DM, Choate R, et al. Genotype is associated with smoking and other key health behaviors among individuals with Alpha-1 antitrypsin deficiency-associated lung disease. Respir Med. 2018;143:48–55. DOI:10.1016/j.rmed.2018.08.016
   PubMed Web of Science ®Google Scholar
• AAPOR. Standard definitions: Final dispositions of case codes and outcome rates for surveys. 9th ed. Washington DC, AAPOR; 2016.
   Google Scholar
• Holm M, Schioler L, Andersson E, et al. Predictors of smoking cessation: a longitudinal study in a large cohort of smokers. Respir Med. 2017;132:164–169. DOI:10.1016/j.rmed.2017.10.013
   PubMed Web of Science ®Google Scholar
• Tonnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013;22(127):37–43. DOI:10.1183/09059180.00007212
   PubMedGoogle Scholar
• Burke L, Miller LA, Saad A, et al. Smoking behaviors among cancer survivors: an observational clinical study. J Oncol Pract. 2009;5(1):6–9. DOI:10.1200/JOP.0912001
   PubMedGoogle Scholar
• Hopenhayn C, Christian WJ, Christian A, et al. Factors associated with smoking abstinence after diagnosis of early stage lung cancer. Lung Cancer. 2013;80(1):55–61. DOI:10.1016/j.lungcan.2012.12.013
   PubMed Web of Science ®Google Scholar
• Stoller JK, Sandhaus RA, Turino G, et al. Delay in diagnosis of Alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989–1994. DOI:10.1378/chest.128.4.1989
   PubMed Web of Science ®Google Scholar
• Greulich T, Ottaviani S, Bals R, et al. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(9):1400–1408. DOI:10.1016/j.rmed.2013.04.023
   PubMed Web of Science ®Google Scholar
• Silverman EK. Risk of lung disease in PI MZ heterozygotes. Current status and future research directions. Ann Am Thorac Soc. 2016;13(Suppl 4):S341–S345. DOI:10.1513/AnnalsATS.201507-437KV
   PubMedGoogle Scholar
• Schnoll RA, James C, Malstrom M, et al. Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med. 2003;25(3):214–222. DOI:10.1207/S15324796ABM2503_07
   PubMed Web of Science ®Google Scholar
• Summary SiI. Available from: https://www.hse.ie/eng/about/who/tobaccocontrol/research/smoking-in-ireland-2019.pdf; Health Service Executive of Ireland (HSE), Dublin. 2019.
   Google Scholar
• Epstein JA, Williams C, Botvin GJ, et al. Psychosocial predictors of cigarette smoking among adolescents living in public housing developments. Tob Control. 1999;8(1):45–52. DOI:10.1136/tc.8.1.45
   PubMed Web of Science ®Google Scholar
• de Vries H, Engels R, Kremers S, et al. Parents' and friends' smoking status as predictors of smoking onset: findings from six European countries. Health Educ Res. 2003;18(5):627–636. DOI:10.1093/her/cyg032
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Pennycooke K, Carroll TP, et al. The impact of smoke exposure on the clinical phenotype of Alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease. COPD. 2015;12(sup1):2–9. DOI:10.3109/15412555.2015.1021913
   PubMedGoogle Scholar
• Chapman KR, Chorostowska-Wynimko J, Koczulla AR, et al. Alpha 1 antitrypsin to treat lung disease in Alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis. 2018;13:419–432. DOI:10.2147/COPD.S149429
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51–60. DOI:10.1016/S2213-2600(16)30430-1
   PubMed Web of Science ®Google Scholar